

PAPERS

1. **Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM, for the ALLHAT Research Group. *Am J Hypertension* 1996; 9 (Part 1):342-360.
2. **Experimental approaches to determining the choice of first step therapy for patients with hypertension.** Whelton PK, Williamson JD, Louis GT, Davis BR, Cutler JA, for the ALLHAT Research Group. *Clinical and Experimental Hypertension* 1996; 18:569-579.
3. **Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. *JAMA* 2000;283:1967-1975.
4. **Baseline characteristics of the 42,448 high risk hypertensives enrolled in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V, Echfeldt J, Hawkins CM, Proschan M, for the ALLHAT Collaborative Research Group. *Hypertension* 2001; 37:19-27.
5. **Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, Simpson LM, Nwachuku C, Furberg CD, for the ALLHAT Collaborative Research Group. *Controlled Clinical Trials* 2001; 22:29-41.
6. **First results from ALLHAT: Implications for management of urban hypertensives.** Kumar A, Wright JT, Haywood LJ. *ABC Digest of Urban Cardiology* 2001; 8: 21-24.
7. **Status of alpha-blocker therapy in the treatment of hypertension: Findings of ALLHAT.** Furberg CD, Cutler JA, Davis BR. *Harrison's Online* (http://harrisonsonline.com/server-java/Arknoid/am ed/harrisons/ex_editorials/edl2856_p01.html) September 19, 2001.
8. **Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC, Ciocon JO, Sweeney ME, Randall OS, for the ALLHAT Collaborative Research Group. *Diabetes Care* 2001; 24:654-658.
9. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical center recruitment experience.** Wright JT, Jr, Cushman WC, Davis BR, Barzilay J, Colon P, Egan D, Lucente T, Nwachuku C, Pressel S, Leenen FHH, Frolkis J, Letterer R, Walsh S, Tobin JN, Deger GE, for the ALLHAT Research Group. *Controlled Clinical Trials* 2001; 22:659-673.
10. **Participant Recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Pressel S, Davis BR, Louis GT, Whelton P, Adroque H, Egan D, Farber M, Payne G, Probstfield J, Ward H, for the ALLHAT Research Group. *Controlled Clinical Trials* 2001; 22:674-686.
11. **Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: Further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** David BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD, for the ALLHAT Collaborative Research Group. *Ann Intern Med* 2002; 137:313-320.
12. **Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone.** Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT, Jr, Williamson JD, Leenen FHH, Einhorn PT, Randall OS, Golden JS, Haywood LJ, for the ALLHAT Collaborative Research Group. *Current Controlled Trials in Cardiovascular Medicine* 2002; 3:10-18. On-line at the following URL, last accessed on March 31, 2003: <http://cvm.controlled-trials.com/content/3/1/10>.
13. **Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. *JAMA* 2002; 288:2981-2997.
14. **Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).** The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. *JAMA* 2002; 288:2998-3007.

15. **Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, for the ALLHAT Collaborative Research Group. *J Clin Hypertens* 2002; 4:393-404.
16. **The ANBP2 and ALLHAT: Conflicting or consistent?** Cutler JA. *J Clin Hypertens* 2003; 5:192-195.
17. **Diuretic versus α -blocker as first-step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. *Hypertension* 2003; 42:239-246.
18. **Characteristics and lipid distribution of a large, high-risk, hypertensive population: The lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Papademetriou V, Piller LB, Ford CE, Gordon D, Hartney TJ, Geraci TS, Reison E, Sumner BM, Wong ND, Nwachuku C, Narayan P, Haywood LJ, Habib G, for the ALLHAT Collaborative Research Group. *J Clin Hypertens* 2003; 5:377-385.
19. **What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia.** Geraci TS, Geraci SA. *J Cardiovascular Nursing* 2003; 18:389-395.

ANCILLARY STUDIES

1. **Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study.** Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. *The Pharmacogenomics Journal* 2002; 2:309-317.

BOOK CHAPTERS

1. **Rationale and Design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cutler JA, Gordon DJ, Davis BR, Wright JT, Furberg CD. In: Black HR, ed. *Clinical Trials in Hypertension* New York, NY: Marcel Dekker; 2001: 531-586.

LETTERS

1. **ALLHAT and Calcium Channel Blockers.** Proschan M, Davis B, Cutler J, Ford C, Furberg C, Grimm R, Oparil S, for the ALLHAT Research Group. *Am J Hypertension* 1997; 10:142-143.

2. **Angiotensin-Converting-Enzyme Inhibitors and Diuretics for Hypertension.** Davis BR, Wright JT, Jr., Cutler JA. *N Engl J Med* 2003; 349:91-92.

ABSTRACTS & PRESENTATIONS

1. **The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial: Design features.** Davis B, for the ALLHAT Research Group. **Abstract:** *Controlled Clinical Trials* 1995; 16(Suppl. 3):475. (Presented at 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April 30-May 3, 1995.)
3. **Selection of Clinical Sites for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Pressel S, Egan D, Ford C, Walsh S, Miertechin N, on behalf of the ALLHAT Research Group. **Abstract:** *Controlled Clinical Trials* 1995; 16(Suppl 3):106. (Presented at 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April 30-May 3, 1995.)
4. **Recruitment success by type of site in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Vanguard.** Egan D, Pressel S, Davis B, on behalf of the ALLHAT Research Group. **Abstract:** *Controlled Clinical Trials* 1995; 16(Suppl 3):106. (Presented at the 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April 30-May 3, 1995.)
5. **Workshop III - Operational perspectives in the conduct of large multicenter clinical trials.** Davis B, for the ALLHAT Research Group. **Abstract:** *Controlled Clinical Trials* 1995; 16(Suppl 3):14. (Presented at the 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April 30-May 3, 1995.)
6. **The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) - Design and initial characteristics.** Cushman WC, for the ALLHAT Research Group. **Abstract:** *Hypertension* 1995; 25:1356. (Presented at the 11th Scientific meeting of the Inter-American Society of Hypertension; Montréal, Quebec; June 17-20, 1995.)
7. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Design and early baseline results.** Grimm RH, Jr, for the ALLHAT Research Group. (Presented at the 11th Asian-Pacific Congress of Cardiology; Bali, Indonesia; September 17-22, 1995.)
8. **Design and Aims of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman WC. (Presented at the Panhellenic Congress on Arterial Hypertension; Greece, March 1, 1996.)

9. **ALLHAT Invited Presentation - "Equal Risk for Equal Pressure?"** Cutler J, Furberg C, Temple R, DeMets D. (Presented at the Society for Clinical Trials Plenary Session; Pittsburgh, PA; May 6, 1996.)
10. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Update on recruitment and baseline characteristic.** Grimm RH, Jr, Davis B, Whelton P, Pressel S, for the ALLHAT Research Group. **Abstract:** *Am J Hypertension* 1996; 9 (Part II): 26A. (Presented at the 11th Scientific Meeting of the American Society of Hypertension: New York, NY; May 15-18, 1996.)
11. **Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Whelton P. **Abstract:** *International Society of Hypertension book of abstracts*, June 1996.
12. **Patient recruitment experience in the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Whelton P, Cutler J, Davis B, Grimm R, Pressel S, Probstfield J, Ward H, for the ALLHAT Research Group. **Abstract:** *J Hypertension* 1996; (Suppl 1):998. (Presented at the 16th Scientific Meeting of the International Society of Hypertension; Glasgow, U.K.; June 23-27, 1996.)
13. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Recruitment update and baseline data.** Wright JT, Jr, Cutler JA, Davis BR, Cushman WC, Pressel S, for the ALLHAT Research Group. **Abstract:** *Conference abstract monograph*. (Presented at the 11th International Interdisciplinary Conference on Hypertension in Blacks; New Orleans, LA; July 14-17 1996.)
14. **Statistical design considerations for a large, simple trial of antihypertensive and lipid lowering treatments.** Davis B, Proschan M, Ford CE, for the ALLHAT Research Group. (Presented at the International Biometric Conference; Amsterdam, Netherlands; July 1-5, 1996.)
15. **Statistical issues in a large, simple trial of antihypertensive and lipid-lowering treatments.** Davis BR, Proschan M, Ford CE, for the ALLHAT Research Group. (Presented at the American Statistical Association Meeting; Chicago, IL; August 4-18, 1996.)
16. **Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Update on Southeastern Clinical Research.** Cushman WC. (Presented at the 3rd Annual Meeting of the Consortium of Southeastern Hypertension Centers; Research Triangle Park, NC; August 15, 1996.)
17. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Design, recruitment experience and baseline characteristics.** Papademetriou V, Grimm KH, Jr, for the ALLHAT Research Group. **Abstract:** ????. (Presented at the 4th International Symposium on Multiple Risk Factors in Cardiovascular Disease; Washington, D.C.: April 23-25, 1997.)
18. **Newer vs. older drugs ± cholesterol lowering: ALLHAT.** Cutler J. (Presented at the WHO-ISH Collaboration Annual Meeting and Clinical Trials Symposium; St. Jean Cap Ferrat, France; May 1-3, 1997.) (No written material associated with this presentation.)
19. **Characteristics of the diabetic cohort in the ALLHAT study.** Barzilay J, Jordan J, Grimm R, Davis B, Oparil S, and the ALLHAT Investigators. **Abstract:** *Hypertension* 1997; 10:86A. (Presented at the 12th Scientific Meeting of the American Society of Hypertension; San Francisco, CA; May 28-31, 1997.)
20. **The impact of external events on on-going clinical trials.** Davis BR, Sacks F, Alderman M, Thornquist M, DeMets DL. **Abstract:** Pending. (Presented at the 2nd Joint Meeting of the Society of Clinical Trials/International Society of Clinical Biostatistics; Boston, MA; July 6-10, 1997.)
21. **A clinical data comparison of African American and Non-African American Participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Brown N, Evans SA. **Abstract:** *Ethnicity and Disease* 1997; 7(Suppl):S25. (Presented at the 12th Interdisciplinary Conference on Hypertension in Blacks; London, England; July 20-24, 1997.)
22. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, ALLHAT.** Oparil S. **Abstract:** ????. (Presented at the 4th International Conference on Preventive Cardiology Satellite Symposium entitled, "Optimal Therapy in the Prevention of CAD"; Montreal, Quebec; June 29-July 3, 1997.)
23. **ALLHAT: The largest clinical trial in hypertension ever undertaken.** Davis BR, Hawkins CM, Cutler JA, Payne G, Ford CE, Pressel S, Gordon D, Nwachuku C, Wright J, Cushman W, Grimm R for the ALLHAT Research Group. (Presented by BR Davis at the 6th International Symposium on Hypertension in the Community: Screening, Investigation, and Therapy, February 8-11, 1998, Geneva, Switzerland.)
24. **Blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman WC, Black HR, Probstfield JL, Holland JJ, Hamilton BP, Margolis K, Nwachuku CE, Payne GH, Ford CE for the ALLHAT Research Group. **Abstract:** *Am J Hypertension* 1998; 11:17A. (Presented by WC Cushman at the 13th Scientific Meeting of the

- American Society of Hypertension, May 13-16, 1998, New York, NY.)
25. **Visit (Vad) and medication (Mad) adherence in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Effect of age and other factors.** Nwachuku CE, Probstfield JL, Ford CE, Payne GH, Grimm RH for the ALLHAT Research Group. **Abstract:** *Am J Hypertension* 1998; 11(Suppl 1):82A. (Presented by CE Ford at the 13th Scientific Meeting of the American Society of Hypertension, May 13-16, 1998, New York, NY.)
 26. **Regional differences in attainment of goal blood pressure (BP) amongst United States (US) treated hypertensives in ALLHAT.** **Abstract:** *J Hypertension* 1998; 16 (Suppl 2):Abstract 97.6. (Presented by R Grimm at the 17th Scientific Meeting of the International Society of Hypertension, Amsterdam, Netherlands, June 6-11, 1998.)
 27. **Racial differences in blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Margolis KL, Cushman WC, Wright JT, Grimm RH, Ford CE, Cutler JA for the ALLHAT Research Group. **Abstract:** *J General Internal Medicine* 1999; 14(Suppl 2):52. (Presented by KL Margolis at the 22nd Annual Meeting of the Society for General Internal Medicine, San Francisco, California, April 30, 1999.)
 28. **ALLHAT Adherence Survival Kit.** Lusk CM, Egan D, Carroll L, Kingry C, Johnson JM, Sullivan S, Probstfield J for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. **Abstract:** *Controlled Clinical Trials* 1999; 20(2S):38S. (Presented by CM Lusk at the 20th Annual Meeting of the Society for Clinical Trials, Anaheim, CA, May 3, 1999.)
 29. **Atrial fibrillation in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) clinical trial at baseline.** Haywood LJ, Crow R, Ford C, for the ALLHAT Research Group. **Abstract:** *Ethnicity and Disease* 1999; 9:293. (Presented by LJ Haywood at the 14th International Interdisciplinary Conference on Hypertension in Blacks, Toronto, Ontario, Canada, July 10-14, 1999.)
 30. **Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: Preliminary Results from ALLHAT.** The ALLHAT Collaborative Research Group. (Presented by C. Furberg and BR Davis at the 49th Annual Scientific Session of the American College of Cardiology, Late-Breaking Clinical Trials in Interventional Cardiology (#72), ANAHEIM, CA, March 15, 2000 [10:45 am-12:15 pm].)
 31. **ALLHAT Adherence Survival Kit.** Lusk CM, Egan D, Carroll L, Kingry C, Johnson JM, Sullivan S, Probstfield J. **Abstract:** *Controlled Clinical Trials* 2000; 21:52S-53S. (Presented by C. Lusk at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
 32. **The role of the regional coordinator in clinical trials: Lessons learned.** Lucente T, Williard A, Hynes J, Johnson J, Kingry C, Letterer R, Pressel S, Ragusa P, Ross S. **Abstract:** *Controlled Clinical Trials* 2000; 21:60S. (Presented by T. Lucente at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
 33. **Clinical center recruitment experience in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Davis BR, Pressel S, Wright J, Cushman W, Barzilay J, Colon P, Egan D, Lucente T, Nwachuku C, Leenen F, Frolkis J, Letterer R, Walsh S, Tobin J, Deger G, for the ALLHAT Research Group. **Abstract:** *Controlled Clinical Trials* 2000; 21:63S-64S. (Presented by B. Davis at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
 34. **Management of participant clinic transfers in a large simple trial – ALLHAT.** Lusk CM, Carroll L, Pressel S. **Abstract:** *Controlled Clinical Trials* 2000; 21:104S. (Presented by S. Pressel at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
 35. **The ascertainment of endpoints by primary care practitioners in a long-term clinical trial.** Piller L, Davis B, Kimmel B, Nwachuku C. **Abstract:** *Controlled Clinical Trials* 2000; 21:104S-105S. (Presented by L. Piller at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
 36. **Using educational grants to improve adherence and retention in ALLHAT.** Kimmel B, Juratovac A, Ragusa P, Piller L, Pressel S, Barry A, Payne G. **Abstract:** *Controlled Clinical Trials* 2000; 21:105S. (Presented by B. Kimmel at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
 37. **Differences in adherence patterns of ALLHAT participants.** Bettencourt J, Ford CE. **Abstract:** *Controlled Clinical Trials* 2000; 21:105S-106S. (Presented by J Bettencourt at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
 38. **Quality control site visits in large, simple trials – The ALLHAT experience.** Pressel S, Lucente T, Carroll L, Bettencourt J. **Abstract:** *Controlled Clinical Trials* 2000; 21:105S-106S. (Presented by S. Pressel at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
 39. **Cardiovascular disease rates in Hispanic and Caribbean hypertensives receiving doxazosin and chlorthalidone in the ALLHAT.** Colon PJ, Wright JT, Ford CE, Cutler JA, for the ALLHAT

- Collaborative Research Group. **Abstract:** *Ethnicity and Disease* 2000; 10:315-316. (Presented by P. Colon at the Joint Meeting of the International Society for Hypertension in Blacks and the 15th Annual Interdisciplinary Conference on Hypertension and Related Risk Factors in Ethnic Populations, July 15-18, 2000, Las Croabas, Puerto Rico.)
40. **Blood pressure control in Hispanic participants in ALLHAT.** Margolis K, Piller L, Lewis C, Goff D, Cushman W, Wright J, Colon P, Ford C. **Abstract:** *Circulation* 2001; 103:1348. (Presented by K. Margolis at the 41st AHA Conference on Cardiovascular Disease Epidemiology and Prevention, San Antonio, Texas, March 2, 2001.)
 41. **Validation of heart failure events in ALLHAT participants assigned to doxazosin and chlorthalidone.** Piller L, Davis B, Cutler J, Cushman W, Probstfield J, Williamson J, Leenen F, Randall O, Golden J, Wright J. **Abstract:** *Am J Hypertension* 2001; 14:180A. (Presented by L. Piller at the 16th Scientific Meeting of the American Society of Hypertension, San Francisco, California, May 2001.)
 42. **Practical Issues in Conducting Multicenter Clinical Trials.** Pressel S. **Abstract:** *Controlled Clinical Trials* 2001; 22:5S. (Presented at the 22nd Annual Meeting of the Society for Clinical Trials, May 20-23, 2001, Denver, Colorado.)
 43. **Conducting clinical trials in private practices: What works and what doesn't.** Ford C. **Abstract:** *Controlled Clinical Trials* 2001; 22:17S. (Presented at the 22nd Annual Meeting of the Society for Clinical Trials, May 20-23, 2001, Denver, Colorado.)
 44. **Closeout Procedures for Clinical Trials.** Davis BR. **Abstract:** *Controlled Clinical Trials* 2001; 22:22S. (Presented at the 22nd Annual Meeting of the Society for Clinical Trials, May 20-23, 2001, Denver, Colorado.)
 45. **Follow-up specialist in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Pressel S, Davis B, Babiak-Vazquez A, deLeon B, Bettencourt J, Nwachuku C. **Abstract:** *Controlled Clinical Trials* 2002; 23:48S. (Presented by S. Pressel at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia.)
 46. **The ALLHAT Clinical Trials Center – Expected and unexpected challenges.** Davis BR, Pressel S, Ford C, Piller L, Bettencourt J, Simpson L, deLeon B, Dunn K. **Abstract:** *Controlled Clinical Trials* 2002; 23:56S. (Presented by B.R. Davis at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia.)
 47. **Closeout procedures in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Pressel S, Davis B, Ford C, Bettencourt J, deLeon B, Piller L, Simpson L, Einhorn P, Furberg C, Geraci T, Margolis K, Rahman M, Juratovac A, Feldman S, Kingry C. **Abstract:** *Controlled Clinical Trials* 2002; 23:57S. (Presented by S. Pressel at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia.)
 48. **Ascertainment of vital statistics using outside databases in ALLHAT.** Simpson L, Pressel S, Piller L, Bettencourt J, deLeon B, Davis B. **Abstract:** *Controlled Clinical Trials* 2002; 23:76S. (Presented by L. Simpson at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia.)
 49. **The review of event reports in ALLHAT.** Piller L, Simpson L, Davis B, Pressel S, deLeon B. **Abstract:** *Controlled Clinical Trials* 2002; 23:77S. (Presented by L. Piller at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia.)
 50. **Baseline characteristics of ALLHAT participants with impaired renal function; association with cardiovascular disease.** Rahman M, Brown C, Coresh J, Eckfeldt J, Jelley M, Kopyt N, Levey A, Pressel S, Reisin E, Walworth C, Davis B and the ALLHAT Collaborative Research Group. **Abstract:** *Am J Hypertension* 2002; 15:175A. (Presented by M. Rahman at the 17th Annual Meeting of the American Society of Hypertension, New York, NY, May 14-18, 2002.)
 51. **Blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman W, Ford CE, Cutler JA, Margolis KL, Davis BR, Bettencourt J, Grimm RH. **Abstract:** *Circulation* 2002; ??? (Presented by W. Cushman at the 75th Annual Scientific Sessions of the American Heart Association, November 17-20, 2002, Chicago, Illinois.)
 52. **ALLHAT results and future directions for hypertension research.** Salive ME. (Presented at the American College of Preventive Medicine Meeting, February 22, 2003, San Diego, California.)
 53. **AHT Results.** Wright J. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.)
 54. **LLT Results.** Haywood J. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.)
 55. **ALLHAT: Results and implications in older ALLHAT patients.** Williamson J. (Presented at the Society of Geriatric Cardiology Meeting, March 31, 2003, Chicago, Illinois.)
 56. **Cardiovascular disease (CVD) outcomes in hypertensive patients with impaired renal**

- function.** Rahman M, Cutler J, Davis B, Pressel S, Whelton P, for the ALLHAT Collaborative Research Group. (Presented by M. Rahman at the National Kidney Foundation 2003 Clinical Meetings, April 2-6, 2003, Dallas, Texas.)
57. **Renal outcomes in hypertensive patients with impaired renal function.** Rahman M, Cutler J, Davis B, Pressel S, Whelton P, for the ALLHAT Collaborative Research Group. . (Presented by M. Rahman at the National Kidney Foundation 2003 Clinical Meetings, April 2-6, 2003, Dallas, Texas.)
58. **Blood pressure control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Ford CE, Margolis KL, Piller L, Cushman WC, Wright JT, Colon PJ, for the ALLHAT Collaborative Research Group. (Presented by CE Ford at the 15th Scientific Meeting of the Inter-American Society of Hypertension, April 27-30, 2003, San Antonio, Texas.)
59. **Clinical Implications of ALLHAT.** Oparil S. (Presented at the 15th Scientific Meeting of the Inter-American Society of Hypertension, April 27-30, 2003, San Antonio, Texas.)
60. **The ANBP2 and ALLHAT.** Cutler J, Barrett S. (Presented at the American Academy of Physician Assistants Meeting, May 26, 2003, New Orleans, Louisiana.)
61. **ALLHAT - Implications for hypertension in the elderly.** Leenen, F. (Presented at the Canadian Geriatrics Society Annual Meeting, May 30-31, 2003, Ottawa, Canada.)
62. **How were step up drugs selected in ALLHAT.** Cushman B. (Presented at the American Diabetes Association Meeting, June 16, 2003, New Orleans, Louisiana.)
63. **ALLHAT vs. ANBP2.** Cushman W. (Presented at the Southern Medical Association Meeting, June 28, 2003, Myrtle Beach, South Carolina.)
64. **Subgroup analysis of blacks and diabetics.** Wright J. (Presented at the National Medical Association Meeting, August 2-7, 2003, Philadelphia, Pennsylvania.)
65. **ALLHAT and JNC 7.** Probstfield J. (Presented at the European Society of Cardiology Meeting, August 30 - September 3, 2003, Vienna, Austria.)
66. **ALLHAT: The Key Findings.** Furberg C. (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)
67. **ALLHAT Results for Subgroups and Secondary Outcomes.** Probstfield JL. (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)
68. **After NHANES, ALLHAT and JNC-VII: How Can We Implement the Findings?** Whelton PK. (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)
69. **Atrial fibrillation at baseline and during follow-up in ALLHAT.** Haywood LJ, Ford CE, Crow RS, Davis BR, Einhorn PT, Williard A, Massie B. [Abstract: *Circulation* 2003; 108\(Suppl IV\):IV-371.](#) (Presented by C. Ford at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida.)
70. **Review of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Heart Failure Validation Study.** Einhorn P, Davis B, Piller L, deLeon B, Simpson L, Kostis J, Levy D, Massie B, Nwachuku C, Black H, Cushman W, for the ALLHAT Collaborative Research Group. [Abstract: *Circulation* 2003; 108\(Suppl IV\):IV-399.](#) (Presented by P. Einhorn at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida.)